Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Kumari Chandrawansa

Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- Or Panitumumab-Refractory Metastatic Colorectal Cancer

Journal of Clinical Oncology

English

Related publications

Cetuximab Plus Irinotecan Versus Panitumumab in Patients With Refractory Metastatic Colorectal Cancer in Ontario, Canada

International Journal of Cancer

Cancer Research

Oncology

2017

English

Phase 1 Pharmacokinetic Study of MK-0646 (Dalotuzumab), an Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody, in Combination With Cetuximab and Irinotecan in Japanese Patients With Advanced Colorectal Cancer

Cancer Chemotherapy and Pharmacology

English

Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab

Clinical Colorectal Cancer

Oncology

Gastroenterology

2013

English

Cetuximab and Platinum-Based Chemoradio- Or Chemotherapy of Patients With Epidermal Growth Factor Receptor Expressing Adenoid Cystic Carcinoma: A Phase II Trial

British Journal of Cancer

Cancer Research

Oncology

2013

English

Cetuximab Retreatment in Patients With Metastatic Colorectal Cancer Who Exhibited a Clinical Benefit in Response to Prior Cetuximab: A Retrospective Study

English

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- And PIK3CA- Wild-Type Metastatic Colorectal Cancer: The AGITG Randomised Phase II ICECREAM Study

Clinical Colorectal Cancer

Oncology

Gastroenterology

2018

English

N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy

Clinical Breast Cancer

Cancer Research

Oncology

2016

English

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Journal of Clinical Oncology

English

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Kumari Chandrawansa

Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- Or Panitumumab-Refractory Metastatic Colorectal Cancer

Related publications

Cetuximab Plus Irinotecan Versus Panitumumab in Patients With Refractory Metastatic Colorectal Cancer in Ontario, Canada

Phase 1 Pharmacokinetic Study of MK-0646 (Dalotuzumab), an Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody, in Combination With Cetuximab and Irinotecan in Japanese Patients With Advanced Colorectal Cancer

Magnetic Resonance Imaging as an Early Indicator of Clinical Outcome in Patients With Metastatic Colorectal Carcinoma Treated With Cetuximab or Panitumumab

Cetuximab and Platinum-Based Chemoradio- Or Chemotherapy of Patients With Epidermal Growth Factor Receptor Expressing Adenoid Cystic Carcinoma: A Phase II Trial

Cetuximab Retreatment in Patients With Metastatic Colorectal Cancer Who Exhibited a Clinical Benefit in Response to Prior Cetuximab: A Retrospective Study

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- And PIK3CA- Wild-Type Metastatic Colorectal Cancer: The AGITG Randomised Phase II ICECREAM Study

N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

Phase II Study of an AKT Inhibitor MK2206 in Patients With Relapsed or Refractory Lymphoma